Skip to main content
PMC home page
Microbiological Reviews logoLink to Microbiological Reviews
. 1980 Sep;44(3):419–448. doi: 10.1128/mr.44.3.419-448.1980

Clostridium botulinum neurotoxin.

H Sugiyama
PMCID: PMC373187  PMID: 6252433

Full text

PDF
419

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arnon S. S., Midura T. F., Clay S. A., Wood R. M., Chin J. Infant botulism. Epidemiological, clinical, and laboratory aspects. JAMA. 1977 May 2;237(18):1946–1951. doi: 10.1001/jama.237.18.1946. [DOI] [PubMed] [Google Scholar]
  2. Arnon S. S., Midura T. F., Damus K., Thompson B., Wood R. M., Chin J. Honey and other environmental risk factors for infant botulism. J Pediatr. 1979 Feb;94(2):331–336. doi: 10.1016/s0022-3476(79)80863-x. [DOI] [PubMed] [Google Scholar]
  3. Arnon S. S., Midura T. F., Damus K., Wood R. M., Chin J. Intestinal infection and toxin production by Clostridium botulinum as one cause of sudden infant death syndrome. Lancet. 1978 Jun 17;1(8077):1273–1277. doi: 10.1016/s0140-6736(78)91264-3. [DOI] [PubMed] [Google Scholar]
  4. Arnon S. S., Werner S. B., Faber H. K., Farr W. H. Infant botulism in 1931. Discovery of a misclassified case. Am J Dis Child. 1979 Jun;133(6):580–582. doi: 10.1001/archpedi.1979.02130060020002. [DOI] [PubMed] [Google Scholar]
  5. BONVENTRE P. F., KEMPE L. L. Physiology of toxin production by Clostridium botulinum types A and B. IV. Activation of the toxin. J Bacteriol. 1960 Jan;79:24–32. doi: 10.1128/jb.79.1.24-32.1960. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. BONVENTRE P. F., KEMPE L. L. Toxicity enhancement of Clostridium botulinum type A and B culture filtrates by proteolytic enzymes. J Bacteriol. 1959 Dec;78:892–893. doi: 10.1128/jb.78.6.892-893.1959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. BROOKS V. B. An intracellular study of the action of repetitive nerve volleys and of botulinum toxin on miniature end-plate potentials. J Physiol. 1956 Nov 28;134(2):264–277. doi: 10.1113/jphysiol.1956.sp005642. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. BURGEN A. S. V., DICKENS F., ZATMAN L. J. The action of botulinum toxin on the neuro-muscular junction. J Physiol. 1949 Aug;109(1-2):10–24. doi: 10.1113/jphysiol.1949.sp004364. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Babel-Guérin E., Boyenval J., Droz B., Dunant Y., Hassig R. Accumulation of calcium in cholinergic axon terminals after nerve activity. Localization by electron microscope radioautography at the nerve-electroplaque junction of Torpedo. Brain Res. 1977 Feb;121(2):348–352. doi: 10.1016/0006-8993(77)90157-3. [DOI] [PubMed] [Google Scholar]
  10. Beers W. H., Reich E. Isolation and characterization of Clostridium botulinum type B toxin. J Biol Chem. 1969 Aug 25;244(16):4473–4479. [PubMed] [Google Scholar]
  11. Benecke R., Takano K., Schmidt J., Henatsch H. D. Tetanus toxin induced actions on spinal Renshaw cells and Ia-inhibitory interneurones during development of local tetanus in the cat. Exp Brain Res. 1977 Mar 30;27(3-4):271–286. doi: 10.1007/BF00235503. [DOI] [PubMed] [Google Scholar]
  12. Betley M. J., Sugiyama H. Noncorrelation between mouse toxicity and serologically assayed toxin in Clostridium botulinum type A culture fluids. Appl Environ Microbiol. 1979 Aug;38(2):297–300. doi: 10.1128/aem.38.2.297-300.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Bigalke H., Dimpfel W., Habermann E. Suppression of 3H-acetylcholine release from primary nerve cell cultures by tetanus and botulinum-A toxin. Naunyn Schmiedebergs Arch Pharmacol. 1978 Jun;303(2):133–138. doi: 10.1007/BF00508058. [DOI] [PubMed] [Google Scholar]
  14. Bizzini B. Tetanus toxin. Microbiol Rev. 1979 Jun;43(2):224–240. doi: 10.1128/mr.43.2.224-240.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Boroff D. A., Chen G. S. On the question of permeability of the blood-brain barrier to botulinum toxin. Int Arch Allergy Appl Immunol. 1975;48(4):495–504. doi: 10.1159/000231337. [DOI] [PubMed] [Google Scholar]
  16. Boroff D. A., Chu-Chen G. Radioimmunoassay for type A toxin of Clostridium botulinum. Appl Microbiol. 1973 Apr;25(4):545–549. doi: 10.1128/am.25.4.545-549.1973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Boroff D. A., Fleck U. Statistical analysis of a rapid in vivo method for the titration of the toxin of Clostridium botulinum. J Bacteriol. 1966 Nov;92(5):1580–1581. doi: 10.1128/jb.92.5.1580-1581.1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Boroff D. A., Meloche H. P., Dasgupta B. R. Amino Acid Analysis of the Isolated and Purified Components from Crystalline Toxin of Clostridium botulinum Type A. Infect Immun. 1970 Nov;2(5):679–680. doi: 10.1128/iai.2.5.679-680.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Boroff D. A., Nyberg S., Höglund S. Electron microscopy of the toxin and hemagglutinin of type A Clostridium botulinum. Infect Immun. 1972 Dec;6(6):1003–1007. doi: 10.1128/iai.6.6.1003-1007.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Boroff D. A., Townend R., Fleck U., DasGupta B. R. Ultracentrifugal analysis of the crystalline toxin and isolated fractions of Clostridium botulinum type A. J Biol Chem. 1966 Nov 25;241(22):5165–5167. [PubMed] [Google Scholar]
  21. Boroff D. A., del Castillo J., Evoy W. H., Steinhardt R. A. Observations on the action of type A botulinum toxin on frog neuromuscular junctions. J Physiol. 1974 Jul;240(2):227–253. doi: 10.1113/jphysiol.1974.sp010608. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Bray J. J., Harris A. J. Dissociation between nerve-muscle transmission and nerve trophic effects on rat diaphragm using type D botulinum toxin. J Physiol. 1975 Dec;253(1):53–77. doi: 10.1113/jphysiol.1975.sp011179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Brown G. W., King G., Sugiyama H. Penicillin-Lysozyme Conversion of Clostridium botulinum Types A and E into Protoplasts and Their Stabilization as L-Form Cultures. J Bacteriol. 1970 Dec;104(3):1325–1331. doi: 10.1128/jb.104.3.1325-1331.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chang C. C., Huang M. C. Comparison of the presynaptic actions of botulinum toxin and beta-bungarotoxin on neuromuscular transmission. Naunyn Schmiedebergs Arch Pharmacol. 1974;282(2):129–142. doi: 10.1007/BF00499028. [DOI] [PubMed] [Google Scholar]
  25. Ciccarelli A. S., Whaley D. N., McCroskey L. M., Gimenez D. F., Dowell V. R., Jr, Hatheway C. L. Cultural and physiological characteristics of Clostridium botulinum type G and the susceptibility of certain animals to its toxin. Appl Environ Microbiol. 1977 Dec;34(6):843–848. doi: 10.1128/aem.34.6.843-848.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Collier R. J. Diphtheria toxin: mode of action and structure. Bacteriol Rev. 1975 Mar;39(1):54–85. doi: 10.1128/br.39.1.54-85.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Cull-Candy S. G., Lundh H., Thesleff S. Effects of botulinum toxin on neuromuscular transmission in the rat. J Physiol. 1976 Aug;260(1):177–203. doi: 10.1113/jphysiol.1976.sp011510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Curtis D. R., De Groat W. C. Tetanus toxin and spinal inhibition. Brain Res. 1968 Aug 26;10(2):208–212. doi: 10.1016/0006-8993(68)90123-6. [DOI] [PubMed] [Google Scholar]
  29. Curtis D. R., Felix D., Game C. J., McCulloch R. M. Tetanus toxin and the synaptic release of GABA. Brain Res. 1973 Mar 15;51:358–362. doi: 10.1016/0006-8993(73)90389-2. [DOI] [PubMed] [Google Scholar]
  30. DUFF J. T., WRIGHT G. G., KLERER J., MOORE D. E., BIBLER R. H. Studies on immunity to toxins of Clostridium botulinum. I. A simplified procedure for isolation of type A toxin. J Bacteriol. 1957 Jan;73(1):42–47. doi: 10.1128/jb.73.1.42-47.1957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. DUFF J. T., WRIGHT G. G., YARINSKY A. Activation of Clostridium botulinum type E toxin by trypsin. J Bacteriol. 1956 Oct;72(4):455–460. doi: 10.1128/jb.72.4.455-460.1956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Das Gupta B. R., Sugiyama H. Role of a protease in natural activation of Clostridium botulinum neurotoxin. Infect Immun. 1972 Oct;6(4):587–590. doi: 10.1128/iai.6.4.587-590.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. DasGupta B. R. Activation of Clostridium botulinum type B toxin by an endogenous enzyme. J Bacteriol. 1971 Dec;108(3):1051–1057. doi: 10.1128/jb.108.3.1051-1057.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. DasGupta B. R., Boroff D. A. Separation of toxin and hemagglutinin from crystalline toxin of Clostridium botulinum type A by anion exchange chromatography and determination of their dimensions by gel filtration. J Biol Chem. 1968 Mar 10;243(5):1065–1072. [PubMed] [Google Scholar]
  35. DasGupta B. R., Sugiyama H. A common subunit structure in Clostridium botulinum type A, B and E toxins. Biochem Biophys Res Commun. 1972 Jul 11;48(1):108–112. doi: 10.1016/0006-291x(72)90350-6. [DOI] [PubMed] [Google Scholar]
  36. DasGupta B. R., Sugiyama H. Comparative sizes of type A and B botulinum neurotoxins. Toxicon. 1977;15(4):357–363. doi: 10.1016/0041-0101(77)90019-8. [DOI] [PubMed] [Google Scholar]
  37. DasGupta B. R., Sugiyama H. Inhibition of Clostridium botulinum types A and B hemagglutinins by sugars. Can J Microbiol. 1977 Sep;23(9):1257–1260. doi: 10.1139/m77-188. [DOI] [PubMed] [Google Scholar]
  38. DasGupta B. R., Sugiyama H. Role of arginine residues in the structure and biological activity of botulinum neurotoxin types A and E. Biochem Biophys Res Commun. 1980 Mar 28;93(2):369–375. doi: 10.1016/0006-291x(80)91086-4. [DOI] [PubMed] [Google Scholar]
  39. DasGupta B. R., Sugiyama H. Single chain and dichain forms of neurotoxin in type F Clostridium botulinum culture. Toxicon. 1977;15(5):466–471. doi: 10.1016/0041-0101(77)90128-3. [DOI] [PubMed] [Google Scholar]
  40. Dasgupta B. R., Boroff D. A., Rothstein E. Chromatographic fractionation of the crystalline toxin of Clostridium botulinum type A. Biochem Biophys Res Commun. 1966 Mar 22;22(6):750–756. doi: 10.1016/0006-291x(66)90212-9. [DOI] [PubMed] [Google Scholar]
  41. Dasgupta B. R., Sugiyama H. Isolation and characterization of a protease from Clostridium botulinum type B. Biochim Biophys Acta. 1972 Jun 16;268(3):719–729. doi: 10.1016/0005-2744(72)90276-8. [DOI] [PubMed] [Google Scholar]
  42. Dasgupta B. R., Sugiyama H. Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immun. 1976 Sep;14(3):680–686. doi: 10.1128/iai.14.3.680-686.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Dimpfel W., Huang R. T., Habermann E. Gangliosides in nervous tissue cultures and binding of 125I-labelled tetanus toxin, a neuronal marker. J Neurochem. 1977 Aug;29(2):329–334. doi: 10.1111/j.1471-4159.1977.tb09626.x. [DOI] [PubMed] [Google Scholar]
  44. Dolman C. E., Chang E. Bacteriophages of Clostridium botulinum. Can J Microbiol. 1972 Jan;18(1):67–76. doi: 10.1139/m72-011. [DOI] [PubMed] [Google Scholar]
  45. Dowell V. R., Jr Infant botulism: new guise for an old disease. Hosp Pract. 1978 Oct;13(10):67–72. doi: 10.1080/21548331.1978.11707416. [DOI] [PubMed] [Google Scholar]
  46. Dowell V. R., Jr, McCroskey L. M., Hatheway C. L., Lombard G. L., Hughes J. M., Merson M. H. Coproexamination for botulinal toxin and clostridium botulinum. A new procedure for laboratory diagnosis of botulism. JAMA. 1977 Oct 24;238(17):1829–1832. [PubMed] [Google Scholar]
  47. Drachman D. B., Fanburg B. L. The effect of botulinum toxin on uptake of calcium by synaptosomes. J Neurochem. 1969 Dec;16(12):1633–1635. doi: 10.1111/j.1471-4159.1969.tb10364.x. [DOI] [PubMed] [Google Scholar]
  48. Duchen L. W. Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry. 1970 Feb;33(1):40–54. doi: 10.1136/jnnp.33.1.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Duchen L. W., Tonge D. A. The effects of implantation of an extra nerve on axonal sprouting usually induced by botulinum toxin in skeletal muscle of the mouse. J Anat. 1977 Sep;124(Pt 1):205–215. [PMC free article] [PubMed] [Google Scholar]
  50. Duchen L. W., Tonge D. A. The effects of tetanus toxin on neuromuscular transmission and on the morphology of motor end-plates in slow and fast skeletal muscle of the mouse. J Physiol. 1973 Jan;228(1):157–172. doi: 10.1113/jphysiol.1973.sp010078. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Dumas M., Schwab M. E., Baumann R., Thoenen H. Retrograde transport of tetanus toxin through a chain of two neurons. Brain Res. 1979 Apr 13;165(2):354–357. doi: 10.1016/0006-8993(79)90569-9. [DOI] [PubMed] [Google Scholar]
  52. Eklund M. W., Poysky F. T. Activation of a toxic component of Clostridium botulinum types C and D by trypsin. Appl Microbiol. 1972 Jul;24(1):108–113. doi: 10.1128/am.24.1.108-113.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Eklund M. W., Poysky F. T. Interconversion of type C and D strains of Clostridium botulinum by specific bacteriophages. Appl Microbiol. 1974 Jan;27(1):251–258. doi: 10.1128/am.27.1.251-258.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Eklund M. W., Poysky F. T., Reed S. M. Bacteriophage and the toxigenicity of Clostridium botulinum type D. Nat New Biol. 1972 Jan 5;235(53):16–17. doi: 10.1038/newbio235016a0. [DOI] [PubMed] [Google Scholar]
  55. Eklund M. W., Poysky F. T., Reed S. M., Smith C. A. Bacteriophage and the toxigenicity of Clostridium botulinum type C. Science. 1971 Apr 30;172(3982):480–482. doi: 10.1126/science.172.3982.480. [DOI] [PubMed] [Google Scholar]
  56. Erdmann G., Wiegand H., Wellhöner H. H. Intraaxonal and extraaxonal transport of 125I-tetanus toxin in early local tetanus. Naunyn Schmiedebergs Arch Pharmacol. 1975;290(4):357–373. doi: 10.1007/BF00499949. [DOI] [PubMed] [Google Scholar]
  57. Fex S., Sonesson B., Thesleff S., Zelená J. Nerve implants in botulinum poisoned mammalian muscle. J Physiol. 1966 Jun;184(4):872–882. doi: 10.1113/jphysiol.1966.sp007953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Giménez D. F., Ciccarelli A. S. Another type of Clostridium botulinum. Zentralbl Bakteriol Orig. 1970;215(2):221–224. [PubMed] [Google Scholar]
  59. Giménez D. F., Ciccarelli A. S. New strains of Clostridium botulinum subtype Af. Zentralbl Bakteriol Orig A. 1978 Apr;240(2):215–220. [PubMed] [Google Scholar]
  60. Giménez D. F., Ciccarelli A. S. Studies on strain 84 of Clostridium botulinum. Zentralbl Bakteriol Orig. 1970;215(2):212–220. [PubMed] [Google Scholar]
  61. Gundersen C. B., Jr, Howard B. D. The effects of botulinum toxin on acetylcholine metabolism in mouse brain slices and synaptosomes. J Neurochem. 1978 Oct;31(4):1005–1013. doi: 10.1111/j.1471-4159.1978.tb00140.x. [DOI] [PubMed] [Google Scholar]
  62. HECKLY R. J., HILDEBRAND G. J., LAMANNA C. On the size of the toxic particle passing the intestinal barrier in botulism. J Exp Med. 1960 Jun 1;111:745–759. doi: 10.1084/jem.111.6.745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. HUGHES R., WHALER B. C. Influence of nerve-ending activity and of drugs on the rate of paralysis of rat diaphragm preparations by Cl. botulinum type A toxin. J Physiol. 1962 Feb;160:221–233. doi: 10.1113/jphysiol.1962.sp006843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Habermann E. 125I-labeled neurotoxin from Clostridium botulinum A: preparation, binding to synaptosomes and ascent to the spinal cord. Naunyn Schmiedebergs Arch Pharmacol. 1974;281(1):47–56. doi: 10.1007/BF00500611. [DOI] [PubMed] [Google Scholar]
  65. Habermann E., Heller I. Direct evidence for the specific fixation of Cl. botulinum A neurotoxin to brain matter. Naunyn Schmiedebergs Arch Pharmacol. 1975;287(1):97–106. doi: 10.1007/BF00632641. [DOI] [PubMed] [Google Scholar]
  66. Habermann W. E. Affinity chromatography of tetanus toxin, tetanus toxoid, and botulinum A toxin on synaptosomes, and differentiation of their acceptors. Naunyn Schmiedebergs Arch Pharmacol. 1976;293(1):1–9. doi: 10.1007/BF00498864. [DOI] [PubMed] [Google Scholar]
  67. Hagenah R., Benecke R., Wiegand H. Effects of type A botulinum toxin on the cholinergic transmission at spinal Renshaw cells and on the inhibitory action at Ia inhibitory interneurones. Naunyn Schmiedebergs Arch Pharmacol. 1977 Oct;299(3):267–272. doi: 10.1007/BF00500319. [DOI] [PubMed] [Google Scholar]
  68. Hanig J. P., Lamanna C. Toxicity of botulinum toxin: a stoichiometric model for the locus of its extraordinary potency and persistence at the neuromuscular junction. J Theor Biol. 1979 Mar 7;77(1):107–113. doi: 10.1016/0022-5193(79)90141-3. [DOI] [PubMed] [Google Scholar]
  69. Hariharan H., Mitchell W. R. Observations on bacteriophages of Clostridium botulinum type C isolates from different sources and the role of certain phages in toxigenicity. Appl Environ Microbiol. 1976 Jul;32(1):145–158. doi: 10.1128/aem.32.1.145-158.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Harris A. J., Miledi R. The effect of type D botulinum toxin on frog neuromuscular junctions. J Physiol. 1971 Sep;217(2):497–515. doi: 10.1113/jphysiol.1971.sp009582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Hauschild A. H., Hilsheimer R. Antigenic and chromatographic identity of two apparently distinct toxins of Clostridium botulinum type A. Can J Microbiol. 1969 Oct;15(10):1129–1132. doi: 10.1139/m69-205. [DOI] [PubMed] [Google Scholar]
  72. Heimach R. C., Champion L. A., Sugiyama H. Botulinal toxin and toxoid as antigens. Proc Soc Exp Biol Med. 1970 Oct;135(1):151–154. doi: 10.3181/00379727-135-35008. [DOI] [PubMed] [Google Scholar]
  73. Helting T. B., Zwisler O. Structure of tetanus toxin. I. Breakdown of the toxin molecule and discrimination between polypeptide fragments. J Biol Chem. 1977 Jan 10;252(1):187–193. [PubMed] [Google Scholar]
  74. Helting T. B., Zwisler O., Wiegandt H. Structure of tetanus toxin. II. Toxin binding to ganglioside. J Biol Chem. 1977 Jan 10;252(1):194–198. [PubMed] [Google Scholar]
  75. Hirokawa N., Kitamura M. Binding of Clostridium botulinum neurotoxin to the presynaptic membrane in the central nervous system. J Cell Biol. 1979 Apr;81(1):43–49. doi: 10.1083/jcb.81.1.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Hirokawa N., Kitamura M. Localization of radioactive I25I-labelled botulinus toxin at the neuromuscular junction of mouse diaphragm. Naunyn Schmiedebergs Arch Pharmacol. 1975;287(1):107–110. doi: 10.1007/BF00632642. [DOI] [PubMed] [Google Scholar]
  77. Holman M. E., Spitzer N. C. Action of botulinum toxin on transmission from sympathetic nerves to the vas deferens. Br J Pharmacol. 1973 Feb;47(2):431–433. doi: 10.1111/j.1476-5381.1973.tb08343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Howard B. D., Wu W. C., Gundersen C. B., Jr Antagonism of botulinum toxin by theophylline. Biochem Biophys Res Commun. 1976 Jul 12;71(1):413–415. doi: 10.1016/0006-291x(76)90298-9. [DOI] [PubMed] [Google Scholar]
  79. Inoue K., Iida H. Bacteriophages of Clostridium botulinum. J Virol. 1968 May;2(5):537–540. doi: 10.1128/jvi.2.5.537-540.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Inoue K., Iida H. Conversion of toxigenicity in Clostridium botulinum type C. Jpn J Microbiol. 1970 Jan;14(1):87–89. doi: 10.1111/j.1348-0421.1970.tb00495.x. [DOI] [PubMed] [Google Scholar]
  81. Inoue K., Iida H. Phage-conversion of toxigenicity in Clostridium botulinum types C and D. Jpn J Med Sci Biol. 1971 Feb;24(1):53–56. [PubMed] [Google Scholar]
  82. Iwasaki M., Sakaguchi G. Acid precipitation of Clostridium botulinum type C and D toxins from whole culture by addition of ribonucleic acid as a precipitation aid. Infect Immun. 1978 Feb;19(2):749–751. doi: 10.1128/iai.19.2.749-751.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Jansen B. C. The toxic antigenic factors produced by Clostridium botulinum types C and D. Onderstepoort J Vet Res. 1971 Jun;38(2):93–98. [PubMed] [Google Scholar]
  84. Johnson J. L., Francis B. S. Taxonomy of the Clostridia: ribosomal ribonucleic acid homologies among the species. J Gen Microbiol. 1975 Jun;88(2):229–244. doi: 10.1099/00221287-88-2-229. [DOI] [PubMed] [Google Scholar]
  85. Kao I., Drachman D. B., Price D. L. Botulinum toxin: mechanism of presynaptic blockade. Science. 1976 Sep 24;193(4259):1256–1258. doi: 10.1126/science.785600. [DOI] [PubMed] [Google Scholar]
  86. Kitamura M. Binding of botulinum neurotoxin to the synaptosome fraction of rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1976 Nov;295(2):171–175. doi: 10.1007/BF00499451. [DOI] [PubMed] [Google Scholar]
  87. Kitamura M., Sakaguchi G. Dissociation and reconstitution of 12-S toxin of Clostridium botulinum type E. Biochim Biophys Acta. 1969 Dec 23;194(2):564–571. doi: 10.1016/0005-2795(69)90118-4. [DOI] [PubMed] [Google Scholar]
  88. Kitamura M., Sakaguchi S., Sakaguchi G. Purification and some properties of Clostridium botulinum type-E toxin. Biochim Biophys Acta. 1968 Oct 21;168(2):207–217. doi: 10.1016/0005-2795(68)90144-x. [DOI] [PubMed] [Google Scholar]
  89. Kitamura M., Sakaguchi S., Sakaguchi G. Significance of 12S toxin of Clostridium botulinum type E. J Bacteriol. 1969 Jun;98(3):1173–1178. doi: 10.1128/jb.98.3.1173-1178.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Knox J., Brown W. P., Spero L. The role of sulfhydryl groups in the activity of type A botulinum toxin. Biochim Biophys Acta. 1970 Aug 21;214(2):350–354. doi: 10.1016/0005-2795(70)90012-7. [DOI] [PubMed] [Google Scholar]
  91. Kondo H., Kondo S., Murata R., Sakaguchi G. Antigenicity of Clostridium botulinum type-E formol toxoid. Jpn J Med Sci Biol. 1969 Apr;22(2):75–85. doi: 10.7883/yoken1952.22.75. [DOI] [PubMed] [Google Scholar]
  92. Kozaki S. Interaction of botulinum type A, B and E derivative toxins with synaptosomes of rat brain. Naunyn Schmiedebergs Arch Pharmacol. 1979 Jul;308(1):67–70. doi: 10.1007/BF00499721. [DOI] [PubMed] [Google Scholar]
  93. Kozaki S., Miyazaki S., Sakaguchi G. Development of antitoxin with each of two complementary fragments of Clostridium botulinum type B derivative toxin. Infect Immun. 1977 Dec;18(3):761–766. doi: 10.1128/iai.18.3.761-766.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Kozaki S., Sakaguchi G. Antigenicites of fragments of Clostridium botulinum type B derivative toxin. Infect Immun. 1975 May;11(5):932–936. doi: 10.1128/iai.11.5.932-936.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  95. Kozaki S., Sakaguchi S., Sakaguchi G. Purification and some properties of progenitor toxins of Clostridium botulinum type B. Infect Immun. 1974 Oct;10(4):750–756. doi: 10.1128/iai.10.4.750-756.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Kriebel M. E., Llados F., Matteson D. R. Spontaneous subminature end-plate potentials in mouse diaphragm muscle: evidence for synchronous release. J Physiol. 1976 Nov;262(3):553–581. doi: 10.1113/jphysiol.1976.sp011610. [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Kryzhanovsky G. N. The mechanism of action of tetanus toxin: effect on synaptic processes and some particular features of toxin binding by the nervous tissue. Naunyn Schmiedebergs Arch Pharmacol. 1973;276(3-4):247–270. doi: 10.1007/BF00499880. [DOI] [PubMed] [Google Scholar]
  98. LAMANNA C., LOWENTHAL J. P. The lack of identity between hemagglutinin and the toxin of type A botulinal organism. J Bacteriol. 1951 Jun;61(6):751–752. doi: 10.1128/jb.61.6.751-752.1951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  99. LAMANNA C. Oral poisoning by bacterial exotoxins exemplified in botulism. Ann N Y Acad Sci. 1960 Nov 21;88:1109–1114. doi: 10.1111/j.1749-6632.1960.tb20100.x. [DOI] [PubMed] [Google Scholar]
  100. Lamanna C., Carr C. J. The botulinal, tetanal, and enterostaphylococcal toxins: a review. Clin Pharmacol Ther. 1967 Mar-Apr;8(2):286–332. doi: 10.1002/cpt196782286. [DOI] [PubMed] [Google Scholar]
  101. Lamanna C., Sakaguchi G. Botulinal toxins and the problem of nomenclature of simple toxins. Bacteriol Rev. 1971 Sep;35(3):242–249. doi: 10.1128/br.35.3.242-249.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Lamanna C., Spero L., Schantz E. J. Dependence of time to death on molecular size of botulinum toxin. Infect Immun. 1970 Apr;1(4):423–424. doi: 10.1128/iai.1.4.423-424.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  103. Ledley F. D., Lee G., Kohn L. D., Habig W. H., Hardegree M. C. Tetanus toxin interactions with thyroid plasma membranes. Implications for structure and function of tetanus toxin receptors and potential pathophysiological significance. J Biol Chem. 1977 Jun 25;252(12):4049–4055. [PubMed] [Google Scholar]
  104. Lee W. H., Riemann H. Correlation of toxic and non-toxic strains of Clostridium botulinum by DNA composition and homology. J Gen Microbiol. 1970 Jan;60(1):117–123. doi: 10.1099/00221287-60-1-117. [DOI] [PubMed] [Google Scholar]
  105. Lee W. H., Riemann H. The genetic relatedness of proteolytic Clostridium botulinum strains. J Gen Microbiol. 1970 Nov;64(1):85–90. doi: 10.1099/00221287-64-1-85. [DOI] [PubMed] [Google Scholar]
  106. Lundh H., Leander S., Thesleff S. Antagonism of the paralysis produced by botulinum toxin in the rat. The effects of tetraethylammonium, guanidine and 4-aminopyridine. J Neurol Sci. 1977 May;32(1):29–43. doi: 10.1016/0022-510x(77)90037-5. [DOI] [PubMed] [Google Scholar]
  107. MOLLER V., SCHEIBEL I. Preliminary report on the isolation of an apparently new type of CI. botulinum. Acta Pathol Microbiol Scand. 1960;48:80–80. doi: 10.1111/j.1699-0463.1960.tb04741.x. [DOI] [PubMed] [Google Scholar]
  108. Matsuda M., Yoneda M. Antigenic substructure of tetanus neurotoxin. Biochem Biophys Res Commun. 1977 Jul 11;77(1):268–274. doi: 10.1016/s0006-291x(77)80192-7. [DOI] [PubMed] [Google Scholar]
  109. Matsuda M., Yoneda M. Isolation and purification of two antigenically active, "complimentary" polypeptide fragments of tetanus neurotoxin. Infect Immun. 1975 Nov;12(5):1147–1153. doi: 10.1128/iai.12.5.1147-1153.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Matsuda M., Yoneda M. Reconstitution of tetanus neurotoxin from two antigenically active polypeptide fragments. Biochem Biophys Res Commun. 1976 Feb 9;68(3):668–674. doi: 10.1016/0006-291x(76)91197-9. [DOI] [PubMed] [Google Scholar]
  111. Mellanby J., Thompson P. A. The effect of tetanus toxin at the neuromuscular junction in the goldfish. J Physiol. 1972 Jul;224(2):407–419. doi: 10.1113/jphysiol.1972.sp009902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Midura T. F., Arnon S. S. Infant botulism. Identification of Clostridium botulinum and its toxins in faeces. Lancet. 1976 Oct 30;2(7992):934–936. doi: 10.1016/s0140-6736(76)90894-1. [DOI] [PubMed] [Google Scholar]
  113. Midura T. F., Snowden S., Wood R. M., Arnon S. S. Isolation of Clostridium botulinum from Honey. J Clin Microbiol. 1979 Feb;9(2):282–283. doi: 10.1128/jcm.9.2.282-283.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  114. Miledi R., Spitzer N. C. Absence of action potentials in frog slow muscle fibres paralysed by botulinum toxin. J Physiol. 1974 Aug;241(1):183–199. doi: 10.1113/jphysiol.1974.sp010648. [DOI] [PMC free article] [PubMed] [Google Scholar]
  115. Mirsky R., Wendon L. M., Black P., Stolkin C., Bray D. Tetanus toxin: a cell surface marker for neurones in culture. Brain Res. 1978 Jun 9;148(1):251–259. doi: 10.1016/0006-8993(78)90399-2. [DOI] [PubMed] [Google Scholar]
  116. Miura T. Isolation and characterization of an esterase-active enzyme from pronase with special reference to activation of Clostridium botulinum type E progenitor toxin. Jpn J Med Sci Biol. 1974 Dec;27(6):285–296. doi: 10.7883/yoken1952.27.285. [DOI] [PubMed] [Google Scholar]
  117. Miyazaki S., Iwasaki M., Sakaguchi G. Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties. Infect Immun. 1977 Aug;17(2):395–401. doi: 10.1128/iai.17.2.395-401.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Miyazaki S., Kozaki S., Sakaguchi S., Sakaguchi G. Comparison of progenitor toxins of nonproteolytic with those of proteolytic Clostridium botulinum Type B. Infect Immun. 1976 Mar;13(3):987–989. doi: 10.1128/iai.13.3.987-989.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  119. Miyazaki S., Sakaguchi G. Experimental botulism in chickens: the cecum as the site of production and absorption of botulinum toxin. Jpn J Med Sci Biol. 1978 Feb;31(1):1–15. doi: 10.7883/yoken1952.31.1. [DOI] [PubMed] [Google Scholar]
  120. Moberg L. J., Sugiyama H. Affinity chromatography purification of type A botulinum neurotoxin from crystalline toxic complex. Appl Environ Microbiol. 1978 May;35(5):878–880. doi: 10.1128/aem.35.5.878-880.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Moberg L. J., Sugiyama H. Microbial ecological basis of infant botulism as studied with germfree mice. Infect Immun. 1979 Aug;25(2):653–657. doi: 10.1128/iai.25.2.653-657.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  122. Moberg L. J., Sugiyama H. The rat as an animal model for infant botulism. Infect Immun. 1980 Aug;29(2):819–821. doi: 10.1128/iai.29.2.819-821.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  123. Nakamura S., Serikawa T., Yamakawa K., Nishida S., Kozaki S., Sakaguchi G. Sporulation and C2 toxin production by Clostridium botulinum type C strains producing no C1 toxin. Microbiol Immunol. 1978;22(10):591–596. doi: 10.1111/j.1348-0421.1978.tb00409.x. [DOI] [PubMed] [Google Scholar]
  124. Nakane A., Iida H. Proteolytic mutants obtained from Clostridium botulinum type E. Appl Environ Microbiol. 1977 Jul;34(1):99–101. doi: 10.1128/aem.34.1.99-101.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Nakane A. Proteases produced by a proteolytic mutant of Clostridium botulinum type E. J Gen Microbiol. 1978 Jul;107(1):85–91. doi: 10.1099/00221287-107-1-85. [DOI] [PubMed] [Google Scholar]
  126. Neubauer V., Helting T. B. Structure of tetanus toxin. N-Terminal amino acid analysis of the two molecular forms of tetanus toxin and its composite chains. Biochem Biophys Res Commun. 1979 Feb 14;86(3):635–642. doi: 10.1016/0006-291x(79)91760-1. [DOI] [PubMed] [Google Scholar]
  127. Notermans S., Dufrenne J., Kozaki S. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum type E toxin. Appl Environ Microbiol. 1979 Jun;37(6):1173–1175. doi: 10.1128/aem.37.6.1173-1175.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  128. Notermans S., Dufrenne J., Schothorst M. Enzyme-linked immunosorbent assay for detection of Clostridium botulinum toxin type A. Jpn J Med Sci Biol. 1978 Feb;31(1):81–85. doi: 10.7883/yoken1952.31.81. [DOI] [PubMed] [Google Scholar]
  129. Oguma K., Iida H. High and low toxin production by a non-toxigenic strain of Clostridium botulinum type C following infection with type C phages of different passage history. J Gen Microbiol. 1979 May;112(1):203–206. doi: 10.1099/00221287-112-1-203. [DOI] [PubMed] [Google Scholar]
  130. Oguma K., Iida H., Inoue K. Observations on nonconverting phage, c-n71, obtained from a nontoxigenic strain of Clostridium botulinum type C. Jpn J Microbiol. 1975 Jun;19(3):167–172. doi: 10.1111/j.1348-0421.1975.tb00864.x. [DOI] [PubMed] [Google Scholar]
  131. Oguma K., Iida H., Shiozaki M., Inoue K. Antigenicity of converting phages obtained from Clostridium botulinum types C and D. Infect Immun. 1976 Mar;13(3):855–860. doi: 10.1128/iai.13.3.855-860.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  132. Oguma K., Iida H., Shiozaki M. Phage conversion to hemagglutinin production in Clostridium botulinum types C and D. Infect Immun. 1976 Sep;14(3):597–602. doi: 10.1128/iai.14.3.597-602.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Oguma K., Sugiyama H. Adsorption to Clostridium botulinum cultures of phage controlling type C botulinum toxin production. Proc Soc Exp Biol Med. 1978 Oct;159(1):61–64. doi: 10.3181/00379727-159-40284. [DOI] [PubMed] [Google Scholar]
  134. Oguma K. The stability of toxigenicity in Clostridium botulinum types C and D. J Gen Microbiol. 1976 Jan;92(1):67–75. doi: 10.1099/00221287-92-1-67. [DOI] [PubMed] [Google Scholar]
  135. Ohishi I., Sakaguchi G. Activation of botulinum toxins in the absence of nicking. Infect Immun. 1977 Aug;17(2):402–407. doi: 10.1128/iai.17.2.402-407.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Ohishi I., Sakaguchi G. Molecular construction of Clostridium botulinum type F progenitor toxin. Appl Microbiol. 1975 Apr;29(4):444–447. doi: 10.1128/am.29.4.444-447.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Ohishi I., Sakaguchi G. Response of type B and E Botulinum toxins to purified sulfhydryl-dependent protease produced by Clostridium botulinum type F. Jpn J Med Sci Biol. 1977 Aug;30(4):179–190. doi: 10.7883/yoken1952.30.179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Ohishi I., Sugii S., Sakaguchi G. Oral toxicities of Clostridium botulinum toxins in response to molecular size. Infect Immun. 1977 Apr;16(1):107–109. doi: 10.1128/iai.16.1.107-109.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  139. Oishi I., Okada T., Sakaguchi G. Responses of Clostridium botulinum type B and E progenitor toxins to some clostridial sulfhydryl-dependent proteases. Jpn J Med Sci Biol. 1975 Jun;28(3):157–164. doi: 10.7883/yoken1952.28.157. [DOI] [PubMed] [Google Scholar]
  140. Oishi I., Sakaguchi G. Purification of Clostridium botuliunum type F progenitor toxin. Appl Microbiol. 1974 Dec;28(6):923–928. doi: 10.1128/am.28.6.923-928.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Osborne R. H., Bradford H. F., Jones D. G. Patterns of amino acid release from nerve-endings isolated from spinal cord and medulla. J Neurochem. 1973 Aug;21(2):407–419. doi: 10.1111/j.1471-4159.1973.tb04260.x. [DOI] [PubMed] [Google Scholar]
  142. Price D. L., Griffin J., Young A., Peck K., Stocks A. Tetanus toxin: direct evidence for retrograde intraaxonal transport. Science. 1975 May 30;188(4191):945–947. doi: 10.1126/science.49080. [DOI] [PubMed] [Google Scholar]
  143. Puggiari M., Cherington M. Botulism and guanidine. Ten years later. JAMA. 1978 Nov 17;240(21):2276–2277. [PubMed] [Google Scholar]
  144. Pumplin D. W., Reese T. S. Action of brown widow spider venom and botulinum toxin on the frog neuromuscular junction examined with the freeze-fracture technique. J Physiol. 1977 Dec;273(2):443–457. doi: 10.1113/jphysiol.1977.sp012103. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Pumplin D. W., del Castillo J. Release of packets of acetylcholine and synaptic vesicle elicited by brown widow spider venom in frog motor nerve endings poisoned by botulinum toxin. Life Sci. 1975 Jul 1;17(1):137–141. doi: 10.1016/0024-3205(75)90249-0. [DOI] [PubMed] [Google Scholar]
  146. SAKAGUCHI G., TOHYAMA Y. Studies on the toxin production of Clostridium botulinum type E. II. The mode of action of the contaminant organisms to promote toxin production of type E organisms. Jpn J Med Sci Biol. 1955 Jun;8(3):255–262. doi: 10.7883/yoken1952.8.255. [DOI] [PubMed] [Google Scholar]
  147. STOVER J. H., Jr, FINGERMAN M., FORESTER R. H. Botulinum toxin and the motor end plate. Proc Soc Exp Biol Med. 1953 Oct;84(1):146–147. doi: 10.3181/00379727-84-20570. [DOI] [PubMed] [Google Scholar]
  148. Sakaguchi G., Sakaguchi S., Karashimada T. Molecular size of Clostridium botulinum type E toxin in "izushi". Jpn J Med Sci Biol. 1966 Aug;19(4):201–207. [PubMed] [Google Scholar]
  149. Sakaguchi G., Sakaguchi S., Kondo H. Rapid bioassay for Clostridium botulinum type-E toxins by intravenous injection into mice. Jpn J Med Sci Biol. 1968 Dec;21(6):369–378. doi: 10.7883/yoken1952.21.369. [DOI] [PubMed] [Google Scholar]
  150. Sakaguchi G., Sakaguchi S., Kozaki S., Sugii S., Oishi I. Cross reaction in reversed passive hemagglutination between Clostridium botulinum type A and B toxins and its avoidance by the sue of anti-toxic component immunoglobulin isolated by affinity chromatography. Jpn J Med Sci Biol. 1974 Jun;27(3):161–172. doi: 10.7883/yoken1952.27.161. [DOI] [PubMed] [Google Scholar]
  151. Schwab M. E., Thoenen H. Electron microscopic evidence for a transsynaptic migration of tetanus toxin in spinal cord motoneurons: an autoradiographic and morphometric study. Brain Res. 1976 Mar 26;105(2):213–227. doi: 10.1016/0006-8993(76)90422-4. [DOI] [PubMed] [Google Scholar]
  152. Scott A. B., Rosenbaum A., Collins C. C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol. 1973 Dec;12(12):924–927. [PubMed] [Google Scholar]
  153. Shield L. K., Wilkinson R. G., Ritchie M. Infant botulism in Australia. Med J Aust. 1978 Aug 12;2(4):157–157. doi: 10.5694/j.1326-5377.1978.tb131427.x. [DOI] [PubMed] [Google Scholar]
  154. Shimizu T., Kondo H. Immunological difference between the toxin of a progeolytic strain and that of a nonproteolytic strain of Clostridium botulinum type B. Jpn J Med Sci Biol. 1973 Dec;26(5):269–271. doi: 10.7883/yoken1952.26.269. [DOI] [PubMed] [Google Scholar]
  155. Simpson L. L., Boroff D. A., Fleck U. Examination of the possible pathophysiology of the central nervous system during botulinal poisoning. Exp Neurol. 1968 Sep;22(1):85–95. doi: 10.1016/0014-4886(68)90021-6. [DOI] [PubMed] [Google Scholar]
  156. Simpson L. L. Ionic requirements for the neuromuscular blocking action of botulinum toxin: implications with regard to synaptic transmission. Neuropharmacology. 1971 Nov;10(6):673–684. doi: 10.1016/0028-3908(71)90082-7. [DOI] [PubMed] [Google Scholar]
  157. Simpson L. L., Morimoto H. Failure to inhibit in vitro or in vivo acetycholinesterase with botulinum toxin type A. J Bacteriol. 1969 Feb;97(2):571–575. doi: 10.1128/jb.97.2.571-575.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Simpson L. L. Pharmacological studies on the subcellular site of action of botulinum toxin type A. J Pharmacol Exp Ther. 1978 Sep;206(3):661–669. [PubMed] [Google Scholar]
  159. Simpson L. L., Rapport M. M. The binding of botulinum toxin to membrane lipids: sphingolipids, steroids and fatty acids. J Neurochem. 1971 Sep;18(9):1751–1759. doi: 10.1111/j.1471-4159.1971.tb03750.x. [DOI] [PubMed] [Google Scholar]
  160. Simpson L. L. Studies on the binding of botulinum toxin type A to the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology. 1974 Aug;13(8):683–691. doi: 10.1016/0028-3908(74)90014-8. [DOI] [PubMed] [Google Scholar]
  161. Simpson L. L. The effects of acute and chronic botulinum toxin treatment on receptor number, receptor distribution and tissue sensitivity in rat diaphragm. J Pharmacol Exp Ther. 1977 Feb;200(2):343–351. [PubMed] [Google Scholar]
  162. Simpson L. L. The interaction between divalent cations and botulinum toxin type A in the paralysis of the rat phrenic nerve-hemidiaphragm preparation. Neuropharmacology. 1973 Feb;12(2):165–176. doi: 10.1016/0028-3908(73)90085-3. [DOI] [PubMed] [Google Scholar]
  163. Smith D. H., Timms G. L., Refai M. Outbreak of botulism in Kenyan nomads. Ann Trop Med Parasitol. 1979 Apr;73(2):145–148. doi: 10.1080/00034983.1979.11687241. [DOI] [PubMed] [Google Scholar]
  164. Solomon H. M., Lynt R. K., Jr, Kautter D. A., Lilly T., Jr Serological studies of Clostridium botulinum type E and related organisms. II. Serology of spores. J Bacteriol. 1969 May;98(2):407–414. doi: 10.1128/jb.98.2.407-414.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Stöckel K., Schwab M., Thoenen H. Comparison between the retrograde axonal transport of nerve growth factor and tetanus toxin in motor, sensory and adrenergic neurons. Brain Res. 1975 Nov 28;99(1):1–16. doi: 10.1016/0006-8993(75)90604-6. [DOI] [PubMed] [Google Scholar]
  166. Sugii S., Ohishi I., Sakaguchi G. Correlation between oral toxicity and in vitro stability of Clostridium botulinum type A and B toxins of different molecular sizes. Infect Immun. 1977 Jun;16(3):910–914. doi: 10.1128/iai.16.3.910-914.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Sugii S., Ohishi I., Sakaguchi G. Intestinal absorption of botulinum toxins of different molecular sizes in rats. Infect Immun. 1977 Sep;17(3):491–496. doi: 10.1128/iai.17.3.491-496.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Sugii S., Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins. Infect Immun. 1975 Dec;12(6):1262–1270. doi: 10.1128/iai.12.6.1262-1270.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Sugiyama H. Animal models for the study of infant botulism. Rev Infect Dis. 1979 Jul-Aug;1(4):683–688. doi: 10.1093/clinids/1.4.683. [DOI] [PubMed] [Google Scholar]
  170. Sugiyama H., Das Gupta R., Yang K. H. Disulfide-toxicity relationship of botulinal toxin types A, E, and F. Proc Soc Exp Biol Med. 1973 Jul;143(3):589–591. doi: 10.3181/00379727-143-37372. [DOI] [PubMed] [Google Scholar]
  171. Sugiyama H., King G. J. Isolation and taxonomic significance of bacteriophages for non-proteolytic Clostridium botulinum. J Gen Microbiol. 1972 May;70(3):517–525. doi: 10.1099/00221287-70-3-517. [DOI] [PubMed] [Google Scholar]
  172. Sugiyama H., Mills D. C. Intraintestinal toxin in infant mice challenged intragastrically with Clostridium botulinum spores. Infect Immun. 1978 Jul;21(1):59–63. doi: 10.1128/iai.21.1.59-63.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Sugiyama H., Mizutani K., Yang K. H. Basis of type A and F toxicities of Clostridium botulinum strain 84. Proc Soc Exp Biol Med. 1972 Dec;141(3):1063–1067. doi: 10.3181/00379727-141-36933. [DOI] [PubMed] [Google Scholar]
  174. Sugiyama H., Moberg L. J., Messer S. L. Improved procedure for crystallization of Clostridium botulinum type A toxic complexes. Appl Environ Microbiol. 1977 Apr;33(4):963–966. doi: 10.1128/aem.33.4.963-966.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Sugiyama H., Oishi I., Dasgupta B. R. Evaluation of type A botulinal toxin assays that use antitoxin to crystalline toxin. Appl Microbiol. 1974 Feb;27(2):333–336. doi: 10.1128/am.27.2.333-336.1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Syuto B., Kubo S. Isolation and molecular size of Clostridium botulinum type C toxin. Appl Environ Microbiol. 1977 Feb;33(2):400–405. doi: 10.1128/aem.33.2.400-405.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Syuto B., Kubo S. Purification and crystallization of Clostridium botulinum type C toxin. Jpn J Vet Res. 1972 Jun;20(1):19–30. [PubMed] [Google Scholar]
  178. THESLEFF S. Supersensitivity of skeletal muscle produced by botulinum toxin. J Physiol. 1960 Jun;151:598–607. doi: 10.1113/jphysiol.1960.sp006463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Terranova W., Breman J. G., Locey R. P., Speck S. Botulism type B: epidemiologic aspects of an extensive outbreak. Am J Epidemiol. 1978 Aug;108(2):150–156. doi: 10.1093/oxfordjournals.aje.a112599. [DOI] [PubMed] [Google Scholar]
  180. Tonge D. A. Chronic effects of botulinum toxin on neuromuscular transmission and sensitivity to acetylcholine in slow and fast skeletal muscle of the mouse. J Physiol. 1974 Aug;241(1):127–139. doi: 10.1113/jphysiol.1974.sp010644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Turner H. D., Brett E. M., Gilbert R. J., Ghosh A. C., Liebeschuetz H. J. Infant botulism in England. Lancet. 1978 Jun 17;1(8077):1277–1278. doi: 10.1016/s0140-6736(78)91265-5. [DOI] [PubMed] [Google Scholar]
  182. WRIGHT G. P. The neurotoxins of Clostridium botulinum and Clostridium tetani. Pharmacol Rev. 1955 Dec;7(4):413–465. [PubMed] [Google Scholar]
  183. Wellhöner H. H., Seib U. C., Hensel B. Local tetanus in cats: the influence of neuromuscular activity on spinal distribution of 125 I labelled tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol. 1973;276(3-4):387–394. doi: 10.1007/BF00499891. [DOI] [PubMed] [Google Scholar]
  184. Wernig A., Stöver H., Tonge D. The labelling of motor end-plates in skeletal muscle of mice with 125I tetanus toxin. Naunyn Schmiedebergs Arch Pharmacol. 1977 May;298(1):37–42. doi: 10.1007/BF00510984. [DOI] [PubMed] [Google Scholar]
  185. Westwood D. A., Whaler B. C. Postganglionic paralysis of the guinea-pig hypogastric nerve-vas deferens preparation by Clostridium botulinum type D toxin. Br J Pharmacol Chemother. 1968 May;33(1):21–31. doi: 10.1111/j.1476-5381.1968.tb00470.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Wiegand H., Erdmann G., Wellhöner H. H. 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol. 1976;292(2):161–165. doi: 10.1007/BF00498587. [DOI] [PubMed] [Google Scholar]
  187. Wiegand H., Wellhöner H. H. Electrical excitability of motoneurones in early local tetanus. Naunyn Schmiedebergs Arch Pharmacol. 1979 Jul;308(1):71–76. doi: 10.1007/BF00499722. [DOI] [PubMed] [Google Scholar]
  188. Wiegand H., Wellhöner H. H. The action of botulinum A neurotoxin on the inhibition by antidromic stimulation of the lumbar monosynaptic reflex. Naunyn Schmiedebergs Arch Pharmacol. 1977 Jul;298(3):235–238. doi: 10.1007/BF00500893. [DOI] [PubMed] [Google Scholar]
  189. Wonnacott S., Marchbanks R. M., Fiol C. Ca2+ uptake by synaptosomes and its effect on the inhibition of acetylcholine release by botulinum toxin. J Neurochem. 1978 May;30(5):1127–1134. doi: 10.1111/j.1471-4159.1978.tb12407.x. [DOI] [PubMed] [Google Scholar]
  190. Wonnacott S., Marchbanks R. M. Inhibition by botulinum toxin of depolarization-evoked release of (14C)acetylcholine from synaptosomes in vitro. Biochem J. 1976 Jun 15;156(3):701–712. doi: 10.1042/bj1560701. [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Yang K. H., Sugiyama H. Purification and properties of Clostridium botulinum type F toxin. Appl Microbiol. 1975 May;29(5):598–603. doi: 10.1128/am.29.5.598-603.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. ZACKS S. I., METZGER J., SMITH C. W., BLUMBERG J. M. Localization of ferritin-labelled botulinus toxin in the neuromuscular junction of the mouse. J Neuropathol Exp Neurol. 1962 Oct;21:610–633. doi: 10.1097/00005072-196210000-00008. [DOI] [PubMed] [Google Scholar]
  193. Zimmerman J. M., Piffaretti J. C. Interaction of tetanus toxin and toxoid with cultured neuroblastoma cells. Analysis by immunofluorescence. Naunyn Schmiedebergs Arch Pharmacol. 1977 Feb;296(3):271–277. doi: 10.1007/BF00498693. [DOI] [PubMed] [Google Scholar]
  194. van Heyningen S. Binding of ganglioside by the chains of tetanus toxin. FEBS Lett. 1976 Sep 15;68(1):5–7. doi: 10.1016/0014-5793(76)80391-2. [DOI] [PubMed] [Google Scholar]
  195. van Heyningen W. E., Mellanby J. A note on the specific fixation, specific deactivation and non-specific inactivation of bacterial toxins by gangliosides. Naunyn Schmiedebergs Arch Pharmacol. 1973;276(3-4):297–302. doi: 10.1007/BF00499883. [DOI] [PubMed] [Google Scholar]

Articles from Microbiological Reviews are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES